- Home
- ALV vs JAZZ Comparison
ALV vs JAZZ Comparison
Compare ALV & JAZZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALV
- JAZZ
- Stock Information
- Founded
- ALV 1953
- JAZZ 2003
- Country
- ALV Sweden
- JAZZ Ireland
- Employees
- ALV N/A
- JAZZ N/A
- Industry
- ALV Auto Parts:O.E.M.
- JAZZ Biotechnology: Pharmaceutical Preparations
- Sector
- ALV Consumer Discretionary
- JAZZ Health Care
- Exchange
- ALV Nasdaq
- JAZZ Nasdaq
- Market Cap
- ALV 7.6B
- JAZZ 8.4B
- IPO Year
- ALV 1997
- JAZZ 2007
- Fundamental
- Price
- ALV $89.17
- JAZZ $122.92
- Analyst Decision
- ALV Buy
- JAZZ Strong Buy
- Analyst Count
- ALV 12
- JAZZ 13
- Target Price
- ALV $119.00
- JAZZ $187.15
- AVG Volume (30 Days)
- ALV 1.1M
- JAZZ 1.3M
- Earning Date
- ALV 04-16-2025
- JAZZ 04-30-2025
- Dividend Yield
- ALV 3.14%
- JAZZ N/A
- EPS Growth
- ALV 40.56
- JAZZ 41.75
- EPS
- ALV 8.04
- JAZZ 8.65
- Revenue
- ALV $10,390,000,000.00
- JAZZ $4,068,950,000.00
- Revenue This Year
- ALV $0.74
- JAZZ $7.30
- Revenue Next Year
- ALV $4.75
- JAZZ $4.01
- P/E Ratio
- ALV $11.10
- JAZZ $14.21
- Revenue Growth
- ALV N/A
- JAZZ 6.12
- 52 Week Low
- ALV $87.55
- JAZZ $99.06
- 52 Week High
- ALV $129.38
- JAZZ $148.06
- Technical
- Relative Strength Index (RSI)
- ALV 41.88
- JAZZ 32.69
- Support Level
- ALV $88.58
- JAZZ $137.74
- Resistance Level
- ALV $95.18
- JAZZ $142.64
- Average True Range (ATR)
- ALV 2.26
- JAZZ 3.87
- MACD
- ALV 0.07
- JAZZ -2.12
- Stochastic Oscillator
- ALV 20.58
- JAZZ 0.45
About ALV Autoliv Inc.
Autoliv is the global leader in passive safety components and systems for the auto industry. Products include seat belts, frontal air bags, side-impact air bags, air bag inflators, and steering wheels. The Renault-Nissan-Mitsubishi alliance is the company's largest customer at 10% of 2023 revenue, with Stellantis accounting for 10% and Volkswagen 9%. At 34% of 2023 revenue, the Americas was Autoliv's largest geographic region, followed by Europe at 27%, China at 20%, and rest of world at 19%.
About JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.